Cosupplementation of isoflavones, prenylflavonoids, and lignans alters human exposure to phytoestrogen-derived 17beta-estradiol equivalents.
The microbial metabolism of dietary phytoestrogens varies considerably among individuals and influences the final exposure to bioactive compounds. In view of the increasing number of food supplements combining several classes of phytoestrogens, the microbial potential to activate various proestrogens within an individual was evaluated in 3 randomized dietary crossovers. Treatment allocation was based on participants' eligibility (>45% in vitro bioactivation of >or=2 separate proestrogens by fecal cultures; n = 40/100). After a run-in of >or=4 d, participants were given soy-, hop-, and/or flax-based food supplements dosed either separately (SOY: 2.83 mg daidzein aglycone equivalents/supplement, HOP: 1.20 mg isoxanthohumol (IX)/supplement, or FLAX: 2.08 mg secoisolariciresinol (SECO) aglycone equivalents/supplement; reference intervention) or simultaneously (MIX; test intervention) 3 times/d for 5 d, followed by a wash-out period (>or=7 d) and the second intervention. Before and after each (co)supplementation, spot urine and serum were collected. In total, 22 equol, 19 8-prenylnaringenin (8-PN), and 21 enterolactone (ENL) producers completed the SOY+MIX, HOP+MIX, and FLAX+MIX trials, respectively. The microbial bioactivation of daidzein, IX, and SECO, generally decreased upon coincubation in vitro (equol: 4.4%, P = 0.164; 8-PN: 20.5%, P < 0.001; ENL: 44.3%, P < 0.001) and cosupplementation in vivo (equol: 28.3%, P = 0.009; 8-PN: 35.4%, P = 0.107; ENL: 35.9%, P = 0.003). Although the bioavailabilities of total isoflavones, prenylflavonoids, and lignans were not significantly affected upon coadministration, participants were exposed to lower phytoestrogen-derived 17beta-estradiol equivalents. In conclusion, the bioavailability of phytoestrogens, especially when given in mixtures, is subject to high interindividual variation. These findings support the importance of personalized screening when assessing the efficacy of such products and mixtures.
Bolca
Selin
S
Faculty of Bioscience Engineering, Ghent University, Ghent, Belgium.
Wyns
Ciska
C
Possemiers
Sam
S
Depypere
Herman
H
De Keukeleire
Denis
D
Bracke
Marc
M
Verstraete
Willy
W
Heyerick
Arne
A
D019587:Dietary Supplements; D060754:Equol; D004958:Estradiol / Q000031:analogs & derivatives* / Q000032:analysis / Q000494:pharmacology; D005243:Feces / Q000737:chemistry; D044950:Flavanones / Q000032:analysis; D005419:Flavonoids / Q000494:pharmacology*; D019833:Genistein / Q000494:pharmacology; D006801:Humans; D007529:Isoflavones / Q000032:analysis / Q000494:pharmacology*; D017705:Lignans / Q000494:pharmacology*; D048789:Phytoestrogens / Q000494:pharmacology*
C007610:4',7-dihydroxy-3,4-dihydroisoflavone; C119737:8-prenylnaringenin; D044950:Flavanones; D005419:Flavonoids; D007529:Isoflavones; D017705:Lignans; D048789:Phytoestrogens; C433163:dihydrodaidzein; D004958:Estradiol; D060754:Equol; C004742:daidzein; C029498:2,3-bis(3'-hydroxybenzyl)butane-1,4-diol; D019833:Genistein